Estrogens and Progression of Diabetic Kidney Damage

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 28-34

  Doublier, Sophie ^a   Lupia, Enrico ^a   Catanuto, Paola ^b,c   Elliot, Sharon J ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Chronic kidney disease; Diabetic kidney damage; Estrogens; Podocytes

Indexed keywords

CAPTOPRIL; CREATININE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE A; GELATINASE B; GESTAGEN; RALOXIFENE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; APOPTOSIS; CELL TYPE; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; CYTOSKELETON; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS BASEMENT MEMBRANE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

EID: 79952763784     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273982     Document Type: Review

References (104)

1. Iliescu R, Reckelhoff JF. Sex and the kidney. Hypertension 2008;51: 1000-1001.
2. Maric C, Sullivan S. Estrogens and the diabetic kidney. Gend Med 2008; 5(Suppl A): S103-S113.
3. Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol 2009; 296: F680-F688.
4. Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 5(Suppl A): S3-S10.
5. Yanes LL, Sartori-Valinotti JC, Reckelhoff JF. Sex steroids and renal disease: lessons from animal studies. Hypertension 2008; 51:976-981.
6. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11: 319-329.
7. Donadio JV Jr., Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988; 33: 708-715.
8. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 1991; 40: 1050-1054.
9. Gretz N, Zeier M, Geberth S, Strauch M, Ritz E. Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1989; 14:178-183.
10. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934-2941.
11. Jafar TH, Schmid CH, Stark PC, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003; 18: 2047-2053.
12. Seliger SL, Davis C, Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001; 10: 219-225.
13. Elliot SJ, Karl M, Berho M, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 2003; 162: 1441-1448.
14. Karl M, Berho M, Pignac-Kobinger J, Striker GE, Elliot SJ. Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: modulation of the mesangial cell phenotype in vivo. Am J Pathol 2006; 169: 351-361.
15. Elliot SJ, Berho M, Korach K, Doublier S, Lupia E, Striker GE, Karl M. Gender-specific effects of endogenous testosterone: Female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int 2007; 72: 464-472.
16. Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep 2004; 6: 377-382.
17. Jacobsen P, Rossing K, Tarnow L, et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999; 71: S101-S105.
18. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67: 1684-1691.
19. Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G. The nephropathy of non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns of renal injury. J Am Soc Nephrol 1998; 9: 2336-2343.
20. Sibley SD, Thomas W, de B, I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006; 47: 223-232.
21. Mangili R, Deferrari G, Di MU, et al. Arterial hypertension and microalbuminuria in IDDM: the Italian Microalbuminuria Study. Diabetologia 1994; 37: 1015-1024.
22. Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 30: 2523-2528.
23. Holl RW, Grabert M, Thon A, Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes: persistent vhs intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 1999; 22: 1555-1560.
24. Laron-Kenet T, Shamis I, Weitzman S, Rosen S, Laron ZV. Mortality of patients with childhood onset (0-17 years) Type I diabetes in Israel: a population-based study. Diabetologia 2001; 44(Suppl 3): B81-B86.
25. Orchard TJ, Dorman JS, Maser RE, et al.Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39: 1116-1124.
26. Schultz CJ, Konopelska-Bahu T, Dalton RN, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999; 22: 495-502.
27. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658.
28. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes. J Clin Endocrinol Metab 2007; 92: 4650-4655.
29. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864.
30. Bain R, Rohde R, Hunsicker LG, McGill J, Kobrin S, Lewis EJ. A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group. J Am Soc Nephrol 1992; 3: S97-S103.
31. Muhlhauser I, Bender R, Bott U, et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996; 13: 536-543.
32. Parving HH, Gall MA, Skott P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762.
33. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
34. Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis 1995; 25: 836-844.
35. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-788.
36. Keane WF, Brenner BM, De ZD, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507.
37. Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis 2001; 38: S191-S194.
38. Crook ED, Patel SR. Diabetic nephropathy in African-American patients. Curr Diab Rep 2004; 4: 455-461.
39. Looker HC, Krakoff J, Funahashi T, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-4017.
40. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003; 26: 2392-2399.
41. Szekacs B, Vajo Z, Varbiro S, et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000; 107: 1017-1021.
42. Agarwal M, Selvan V, Freedman BI, Liu Y, Wagenknecht LE. The relationship between albuminuria and hormone therapy in postmenopausal women. Am J Kidney Dis 2005; 45: 1019-1025.
43. Hadjadj S, Gourdy P, Zaoui P, et al. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial. Diabet Med 2007; 24: 906-910.
44. Monster TB, Janssen WM, De Jong PE, de Jong-van denBerg LT. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001; 161: 2000-2005.
45. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD. HRT does not improve urinary albumin excretion in postmeno-pausal diabetic women. Diabetes Res Clin Pract 2003; 60: 33-39.
46. Ahmed SB, Hovind P, Parving HH, et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005; 28: 1988-1994.
47. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994; 271: 1099-1102.
48. Dixon A, Maric C. 17{beta}-estradiol attenuates diabetic kidney disease via regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol Renal Physiol 2007; 293(5): F1678-F1690.
49. Keck M, Romero-Aleshire MJ, Cai Q, Hoyer PB, Brooks HL. Hormonal status affects the progression of STZ-induced diabetes and diabetic renal damage in the VCD mouse model of menopause. Am J Physiol Renal Physiol 2007; 293(1): F193-F199.
50. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F399-F405.
51. Mankhey RW, Wells CC, Bhatti F, Maric C. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 2007; 292: R769-R777.
52. Catanuto P., Doublier S, Fornoni A, et al. 17-estradiol and Tamoxifen upregulate estrogen receptor β and regulate podocyte signaling pathways in a model of type 2 diabetes. Kidney Int 2009; 75: 1194-1201.
53. Chin M, Isono M, Isshiki K, et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005; 166: 1629-1636.
54. Dixon A, Wells CC, Singh S, Babayan R, Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Am J Nephrol 2007; 27: 120-128.
55. Tomiyoshi Y, Sakemi T, Aoki S, Miyazono M. Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Nephron 2002; 92: 860-867.
56. Rosenmann E, Yanko L, Cohen AM. Female sex hormone and nephropathy in Cohen diabetic rat (genetically selected sucrose-fed). Horm Metab Res 1984; 16: 11-16.
57. Lovegrove AS, Sun J, Gould KA, Lubahn DB, Korach KS, Lane PH. Estrogen receptor alpha-mediated events promote sex-specific diabetic glomerular hypertrophy. Am J Physiol Renal Physiol 2004; 287: F586-F591.
58. Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 2003; 7: 255-259.
59. Barisoni L. Mundel P. Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 2003; 23: 353-360.
60. Kretzler M. Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol 2005; 16: 2830-2832.
61. Ly J, Alexander M, Quaggin SE. A podocentric view of nephrology. Curr Opin Nephrol Hypertens 2004; 13: 299-305.
62. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
63. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
64. McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004; 48(Suppl 1): S7-S12.
65. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833-842.
66. Bhat HK, Hacker HJ, Bannasch P, Thompson EA, Liehr JG. Localization of estrogen receptors in interstitial cells of hamster kidney and in estradiol-induced renal tumors as evidence of the mesenchymal origin of this neoplasm. Cancer Res 1993; 53: 5447-5451.
67. Potier M, Elliot SJ, Tack I, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J Am Soc Nephrol 2001; 12: 241-251.
68. Rogers JL, Mitchell AR, Maric C, Sandberg K, Myers A, Mulroney SE. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am J Physiol Regul Integr Comp Physiol 2007; 292: R794-R799.
69. Wells CC, Riazi S, Mankhey RW, Bhatti F, Ecelbarger C, Maric C. Diabetic nephropathy is associated with decreased circulating estradiol levels and imbalance in the expression of renal estrogen receptors. Gend Med 2005; 2: 227-237.
70. Brockmann R, Beyer A, Heinisch JJ, Wilhelm T. Posttran-scriptional expression regulation: what determines translation rates? PLoS Comput Biol 2007; 3: e57.
71. Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J, White INH. Influence of oestradiol and tamoxifen on oestrogen receptors-{α} and -{β} protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 2005; 35: 421-432.
72. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2007; 105(3): 297-309.
73. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK. The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr Opin Nephrol Hyperten 2008; 17.
74. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009; 111: 9-15.
75. Elliot S, Catanuto P, Doublier S, Lupia E, Fornoni A, Karl MET. Induce changes in steroid hormone receptor expression on podocytes isolated from a model of type 2 diabetes. Annual Meeting of the American Society of Nephrology, November 2005.
76. Tejada T, Catanuto P, Ijaz A, et al. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008; 73(12): 1385-1393.
77. Chen JQ, Cammarata PR, Baines CP, Yager JD. Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochim Biophys Acta 2009; 1793: 1540-1570.
78. Goldfarb S, Ziyadeh FN. TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 2001; 112: 27-32.
79. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
80. Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469.
81. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004; 15(Suppl 1): S55-S57.
82. Benigni A, Zoja C, Campana M, et al. Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 2006; 104: e158-e168.
83. Niranjan T, Murea M, Susztak K. The pathogenic role of notch activation in podocytes. Nephron Exp Nephrol 2009; 111: e73-e79.
84. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008; 14: 290-298.
85. Kanwar YS, Wada J, Sun L, et al. Diabetic Nephropathy: Mechanisms of Renal Disease Progression. Proc Soc Exp Biol Med 2008; 233: 4-11.
86. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005; 24: 5742-5750.
87. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-635.
88. Schnaper HW, Jandeska S, Runyan CE, et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009; 14: 2448-2465.
89. Cherlet T, Murphy LC. Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors. Mol Cell Biochem 2007; 306: 33-42.
90. Sakai N, Wada T, Furuichi K, et al. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 2005; 45: 54-65.
91. Hayashida T, Poncelet AC, Hubchak SC, Schnaper HW. TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 1999; 56: 1710-1720.
92. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 2003; 17: 1576-1578.
93. Lenz O, Elliot SJ, Stetler-Stevenson WG. Matrix metallopro-teinases in renal development and disease. J Am Soc Nephrol 2000; 11: 574-581.
94. Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009; 5: 463-468.
95. Asanuma K, Shirato I, Ishidoh K, Kominami E, Tomino Y. Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int 2002; 62: 822-831.
96. Bai S, Cao X. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-beta signaling. J Biol Chem 2002; 277: 4176-4182.
97. Garg P, Verma R, Holzman LB. Slit diaphragm junctional complex and regulation of the cytoskeleton. Nephron Exp Nephrol 2007; 106: e67-e72.
98. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17: 428-437.
99. Mundel P, Kriz W. Structure and function of podocytes: an update. Anat Embryol (Berl) 1995; 192: 385-397.
100. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007; 106: 26-31.
101. Bijian K, Cybulsky AV. Stress proteins in glomerular epithelial cell injury. Contrib Nephrol 2005; 148: 8-20.
102. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009; 66: 3289-3307.
103. Hou Y, Wei H, Luo Y, Liu G. Modulating expression of brain heat shock proteins by estrogen in ovariectomized mice model of aging. Exp Gerontol 2010; 45: 323-330.
104. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW. Biological and clinical implications of heat shock protein 27000 (Hsp27): a review. J Natl Cancer Inst 1993; 85: 1558-1570.